Neurocrine Biosciences (NBIX) Tops Q4 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Neurocrine Bio. (NBIX) PT Raised to $100 at H.C. Wainwright on Positive Survey Data
February 16, 2017 7:47 AM ESTHC Wainwright and Co. analyst Andrew Fein reiterates Buy rating and raises price target on Neurocrine Biosciences (NASDAQ: NBIX) to $100 (from $80), suggesting the company's shares are undervalued by nearly 60%, as proprietary physician surveys help identify the proper value post Opicapone deal.
Fein writes, "Correcting the value proposition surrounding opicapone. In our view, last week's... More
Needham & Company Reiterates Buy Rating and $62 PT on Neurocrine Biosciences (NBIX) Ahead of 2017 Catalyst
February 15, 2017 7:58 AM ESTNeedham & Company analyst Alan Carr reiterates Buy and $62 price target on Neurocrine Biosciences (NASDAQ: NBIX), as the company remains focused on upcoming Ingrezza launch and Phase 2 pediatric Tourette Syndrome data due May 2017.
Carr comments, "Company continues to prepare for Ingrezza launch ahead of... More
Baird Reiterates Outperform Rating and $66 PT on Neurocrine Biosciences (NBIX) Following 4Q Results
February 15, 2017 5:56 AM ESTBaird analyst Brian Skorney reiterates Outperform rating and $66 price target on Neurocrine Biosciences (NASDAQ: NBIX), noting the company reported in-line results ahead of Ingrezza launch.
Skorney comments, "No change to outlook heading into Ingrezza approval. Neurocrine reported a solid end to the year, modestly... More
